NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Fintel reports that on March 7, 2025, Stifel downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy to ...

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report)‘s stock had its “sector perform” rating reaffirmed by investment ...

Research analysts at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a research report issued to clients and investors on Tuesday, March ...

Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") of a class action securities ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been fil ...

Neumora Therapeutics (NASDAQ:NMRA) stock drops 11% as Stifel downgrades nothing that J&J (JNJ) discontinues a drug similar to NMRA's lead asset. Read more here.

After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

On Friday, Stifel analysts adjusted their stance on Neumora Therapeutics shares, downgrading the biopharmaceutical company from Buy to Hold. The downgrade comes with a significant reduction in the ...